// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Knee osteoarthritis and risk of ten cancers in a large real-world matched cohort study

A. Turkiewicz - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Knee osteoarthritis

N/A

Occupational risk in knee osteoarthritis: a systematic review and meta-analysis

X. Wang - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Incidence and progression of foot osteoarthritis: the Johnston county osteoarthritis project

R. ElTaraboulsi - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

A systematic review of risk factors and diagnostic methods for hand interphalangeal joint osteoarthritis progression

K. Shah - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Comparing of reliability, construct validity and responsiveness of the IPAQ-SF and pase in adults with osteoarthritis

R.D. Smith - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Association between diet quality in childhood and adulthood and knee symptoms in young adults

T. Meng - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

A descriptive baseline analysis of the health of adults longitudinal observational (halo) study - the Australian cohort

L.P. Sutton - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An evaluation of a cycling and education programme for patients referred to secondary care for surgical opinion of hip osteoarthritis

T.W. Wainwright - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Development of a core capability framework for qualified health professionals to optimise care for people with osteoarthritis

R.S. Hinman - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Higher quality of care and less surgery after implementing osteoarthritis guidelines in primary care - long-term results from a cluster-randomized controlled trial

N. asteras - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Association between receiving different elements of care and satisfaction with care in patients with knee osteoarthritis treated by their general practitioner

L. Baumbach - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

What are the clinical, methodological, logistical and operational challenges when designing and conducting a randomised controlled trial of a group based intervention for the treatment of osteoarthritis and how can they be managed?

E.P. Parkinson - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Hydroxyzine

Use of an activity tracker as a measurement tool in a knee osteoarthritis clinical trial (active-oa trial)

S.P. Yu - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

The efficacy of non-surgical and non-pharmacological treatment options in the management of adults with osteoarthritis of the foot and ankle. a systematic review

M.J. Callaghan - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Impact of comorbidities on short-term outcomes from supervised exercise therapy and education - a cohort study of 24,492 patients with knee or hip osteoarthritis

K. Pihl - Osteoarthritis Research Society International (OARSI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

N/A

2020 OA vision: emerging therapeutics on the OA landscape

P. Conaghan - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Triamcinolone acetonide

A year in review: genetics, genomics, epigenetics

L. Reynard - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Osteoarthritis of the foot and ankle

M. Marshall - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

A machine learning “APPROACH” to recruitment in OA

P. Widera - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Implementing international osteoarthritis guidelines in primary care: Results on symptom-related outcomes in secondary analyses from a randomized controlled study

T. Moseng - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

N/A

Copyright © 2026. QuantiNova All rights reserved